You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Seattle-based firm believes its novel collection devices are convenient and safe enough to use at home to draw blood for many types of tests.
Comparing the BD and Quidel rapid antigen tests showed they performed similarly despite sensitivity differences in initial FDA filings.
The lateral flow test developed by Mologic to detect IgA, IgG, and IgM antibodies at the point of care has undergone independent validation.
The firm said that in addition to home use, its test for SARS-CoV-2 antibodies could be used in clinics and hospital emergency rooms.
As the US tries to get more people tested, rapid antigen tests have moved to the forefront of that effort as they can provide results more quickly than PCR-based tests.
Avalon said that as part of the agreement it is working with Cellex to source manufacturing facilities and develop next-generation COVID-19 testing kits.
The chemiluminescent test targets antibodies against the virus' S1 protein which the firm believes is a particularly clinically relevant marker.
About 3.4 million people, or 6 percent of the population in England, was likely infected by SARS-CoV-2 by July 13. People of color had higher rates of infection.
The company developed the test with labs at Emory University, Stanford University, the University of Cincinnati, and the University Health Network in Toronto.
The firm said that its financial results for the second quarter of 2020 reflected the impact of an FDA revocation of an EUA for its DPP COVID-19 IgM/IgG System.